DefineMBC
Commercial- Indications
- Breast cancer
Company intelligence / Profile preview
Epic Sciences has developed and commercialized liquid biopsy tests that analyze circulating tumor cells to guide therapy selection, monitor disease progression, and support drug development. Its Oncotype DX™ AR-V7 Nucleus Detect test is used for treatment decisions in metastatic castrate-resistant prostate cancer. The company partners with major pharma companies for clinical trial support and continues to expand its single-cell sequencing capabilities.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Epic Sciences.